ARTICLE | Clinical News

Forodesine: Phase II data

September 20, 2010 7:00 AM UTC

Top-line data from an open-label, international Phase II trial in 101 patients with stage IIB-IVA CTCL who had received >=3 prior systemic therapies showed that once-daily 200 mg oral forodesine produced an ORR of 11%, with 11 partial responses, plus 56 cases of stable disease. BioCryst said the sample size was too small to determine statistical significance of the data, but that based on the results, it does not plan to conduct any additional trials in the indication. The company also said the response rate may reflect the effect of heavy pretreatment with multiple prior lines of therapy. ...